ALTRIA GROUP, INC.

MO· FY2025 10-K· Analyzed 1 mo ago
PASS
Growth Rates — CAGR from SEC 10-K XBRL filings
Revenue
-0.9%
FY2015–2025
Net Income
3.2%
FY2015–2025
Free Cash Flow
4.9%
FY2015–2025
EPS (Diluted)
24.1%
FY2012–2025
Latest Metrics — FY2025 · SEC XBRL
Return on Equity
157.3%
NI ÷ Equity
Return on Assets
19.8%
NI ÷ Assets
Net Profit Margin
29.8%
NI ÷ Revenue
Debt / Equity
-7.34x
LT Debt ÷ Equity
Intrinsic Value Estimate — DCF (10% discount · 3% terminal · FCF growth capped 15%)
Total Business Value
$76.5B
Per Share (approx.)
$45.68
25% Margin of Safety
$34.26
Conservative entry
50% Margin of Safety
$22.84
Buffett's ideal entry
Growth Rate Used
-0.9%
Latest FCF
$6.9B

Berkshire requires a 25–50% discount to intrinsic value before buying.

Buffett Quality Checklist
ROE >15% consistently (≥7 of last 10 years)
Free cash flow positive (≥8 of last 10 years)
Conservative leverage — Debt/Equity below 1
Revenue growing at CAGR >5%
EPS growing at CAGR >5%
10-Year Financial History — SEC EDGAR 10-K Filings
YearRevenueNet IncomeFCFOwner EarningsROENet MarginLT DebtCash
2016$25.7B$14.2B$3.6B$14.3B111.5%55.3%$13.9B$4.6B
2017$25.6B$10.2B$4.7B$10.2B66.5%40.0%$13.9B$1.3B
2018$25.4B$7.0B$8.2B$7.0B47.1%27.5%$13.0B$1.3B
2019$25.1B-$1.3B$7.6B-$1.3B-20.8%-5.1%$28.0B$2.1B
2020$26.2B$4.5B$8.2B$4.5B157.3%17.1%$29.5B$4.9B
2021$26.0B$2.5B$8.2B$2.5B9.5%$28.0B$4.5B
2022$25.1B$5.8B$8.1B$5.8B23.0%$26.7B$4.0B
2023$24.5B$8.1B$9.1B$8.2B33.2%$26.2B$3.7B
2024$24.0B$11.3B$8.6B$11.4B46.9%$24.9B$3.1B
2025$23.3B$6.9B$9.1B$7.0B29.8%$25.7B$4.5B
Warren & Charlie
Buffett / Munger — quality, moat & valuation

ALTRIA GROUP, INC. (MO) — Investment Memo

🐂 The Bull Case (Warren's voice)

The beauty of a business that sells a habit is that the customer does the marketing for you.

  • The Ultimate Pricing Power: Altria possesses the rare ability to raise prices faster than volume declines. This is a classic toll bridge—the users are captive, the demand is inelastic, and the cost to maintain the moat is negligible.
  • Regulatory Protectionism: While the FDA is a headache, it is also a shield. The barrier to entry for a new combustible cigarette brand is effectively infinite. The government has inadvertently created a legal oligopoly.
  • Cash Flow Primacy: Forget the accounting noise and the "hallucination" of ROE. This business generates staggering FCF with almost zero requirement for capital reinvestment. It is a pure cash-extraction play.
  • Attractive Entry: This becomes a Berkshire-grade asset only when the market prices it as a "melting ice cube" with zero future growth. We want it at a price where the dividend yield alone provides a massive cushion against the slow decay of the core product.

🐻 The Bear Case (Charlie inverts)

"If you're betting on the competence of management to 'pivot' a dying habit, you're a fool."

  • The "Regulatory Guillotine": The permanent impairment scenario isn't a slow decline, but a sudden, structural blow—such as a federal ban on menthols or a mandate for "non-addictive" nicotine levels. This would collapse the pricing power overnight.
  • The Substitution Gap: The core business is leaking. If the transition to smoke-free products (NGP) continues to be characterized by expensive failures (JUUL, Cronos) rather than organic adoption, the revenue leak becomes a flood.
  • Capital Allocation Malpractice: Management has proven a chronic tendency to "chase the shiny object" with shareholder cash. They are gambling with the house money on speculative bets to fix a problem that may be structurally unsolvable.
  • Most Likely Path: A steady, irreversible decline in volume accelerated by a "lollapalooza" effect of regulatory pressure and societal stigma, occurring over the next 5–10 years.

💰 Valuation & Margin of Safety

The DCF treats this as a slow-motion liquidation. We must be colder still.

  • Intrinsic value estimate: $45.68 per share.
  • 25% margin of safety entry: $34.26 (Conservative).
  • 50% margin of safety entry: $22.84 (Buffett's ideal).
  • Current Status: Based on the DCF, the business is dangerously priced if trading anywhere near $45. Unless the stock is trading in the $30s, we are paying for a growth story that doesn't exist and a management team we don't trust.

Verdict: PASS

The intrinsic value of $45.68 offers no meaningful cushion against structural regulatory risks. While the cash flow is seductive, the history of catastrophic capital allocation makes the moat feel like a trap. We will not pay a fair price for a business in permanent retreat.

Other Analyst Views· Lynch · Damodaran
Research Notes· Money Model · Moat · Financials · Management

Data sourced from SEC EDGAR XBRL filings (10-K only). For educational purposes — not investment advice.